Use of the BRAF inhibitor vemurafenib (Zelboraf) combined with the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) led to high rates of complete remission as frontline therapy for patients with ...
Tucatinib combined with trastuzumab and pertuzumab extended PFS in HER2-positive metastatic breast cancer patients, showing a median PFS of 24.9 months versus 16.3 months with placebo. The PFS benefit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback